Results 21 to 30 of about 21,646 (232)
Dabigatran Acylglucuronide, the Major Metabolite of Dabigatran, Shows a Weaker Anticoagulant Effect than Dabigatran [PDF]
Pharmaceutics, 2022 Dabigatran (DAB) is an orally administered thrombin inhibitor. Both DAB and its main metabolite dabigatran acylglucuronide (DABG) have established anticoagulant effects. Here, we aimed to compare the relative anticoagulant effects of DABG and DAB in humans.
Jong-Min Kim +7 more
openaire +3 more sources
The preoperative management of dabigatran and its specific antidote idarucizumab in patients with nonvalvular atrial fibrillation: Case reports [PDF]
Arhiv za farmaciju, 2020 Dabigatran is a novel oral anticoagulant preferred due to its ease of use, favorable pharmacokinetics, decreased potential for drug-drug interactions, and the lack of monitoring requirements.
Tomić Milan
doaj +1 more source
American Journal of Neuroradiology, 2012 Dabigatran (Pradaxa) is a member of the relatively new class of antithrombotic drugs known as direct thrombin inhibitors (DTIs). It may supplant warfarin (Coumadin) in a number of applications as it may produce a more predictable, potent, and immediate anticoagulant effect, with fewer significant side effects and interactions, and requires less ...
J, Comin, D F, Kallmes
openaire +2 more sources
Impact of Dabigatran Treatment on Rotation Thromboelastometry
Clinical and Applied Thrombosis/Hemostasis, 2021 A rapid and reliable assessment of the dabigatran effect is desirable in dabigatran treated patients with uncontrolled bleeding or before acute surgery.
Juraj Sokol MD, PhD +8 more
doaj +1 more source
Measurement of Dabigatran Concentration Using Finger Prick Dried Blood Spot Sample Collection
Frontiers in Pharmacology, 2021 Background and Purpose: Real-world laboratory monitoring of dabigatran activity is challenging. The purpose of the present study was to demonstrate the feasibility and accuracy of finger prick sampling with dried blood spot (fpDBS) cards in measuring the
Shin-Yi Lin +7 more
doaj +1 more source
Global Cardiology Science and Practice, 2014 In the June 2013 issue of this Journal, we described compelling evidence for the use of three novel anticoagulants, including Dabigatran, on the basis of recent large multi-centre trials.1 We acknowledged the approval of NOACs over warfarin in the ESC update and ACCP guidelines, and foresaw the greater usage of these newer, promising, therapies for ...
Kaba, Riyaz A +3 more
openaire +2 more sources
Journal of Arrhythmia, 2015 Background: Activated partial thromboplastin time (aPTT) is recommended for monitoring anticoagulant activity in dabigatran-treated patients; however, there are limited data in Japanese patients.
Daiki Shimomura +14 more
doaj +1 more source
Dabigatran etexilate tetrahydrate [PDF]
Acta Crystallographica Section E Structure Reports Online, 2012 In the title compound, C34H41N7O5·4H2O (systematic name: ethyl 3-{[2-({4-[(Z)-amino-(hexyl-oxycarbonyl-imino)-meth-yl]anilino}meth-yl)-1-meth-yl-benzimidazole-5-carbon-yl]pyridin-2-yl-amino}-propano-ate tetra-hydrate), the benzene and pyridine rings form dihedral angles of 5.4 (1) and 43.8 (1)°, respectively, with the benzimidazole mean plane.
Hong-Qiang Liu +4 more
openaire +3 more sources
HOW TO USE DABIGATRAN IN PATIENTS WITH ATRIAL FIBRILLATION
Рациональная фармакотерапия в кардиологии, 2015 Dabigatran is the new oral anticoagulant that directly inhibits thrombin (factor IIa). In RE-LY clinical trial dabigatran 150 mg b.i.d was more effective than warfarin in prevention of ischemic stroke and systemic embolic events in more than 18000 ...
S. V. Moiseev
doaj +3 more sources
Case Reports in Critical Care, 2016 Purpose. To report the ability to remove serum dabigatran using continuous renal replacement therapy (CRRT) in a patient with life-threatening bleeding. Summary.
Sara E. Parli +2 more
doaj +1 more source